Diagnostic and Treatment Approach for Insulinoma

Diagnostic Approach

• Patients with suspected insulinoma typically present with neuroglycopenic symptoms, such as confusion, lethargy, and seizures, and may experience weight gain due to frequent eating to avoid hypoglycemia, as recommended by the National Comprehensive Cancer Network 1, 2
• Symptoms often occur during fasting, particularly in the morning, according to the Gut journal 3
• The National Comprehensive Cancer Network recommends a supervised fast of 48-72 hours as the first-line test for diagnosing insulinoma, until hypoglycemia occurs or the time limit is reached 1, 3
• At the termination of the fast, diagnostic criteria include an insulin level >3 mcIU/mL, a C-peptide ≥0.6 ng/mL, and proinsulin levels ≥5 pmol/L, as stated by the National Comprehensive Cancer Network 1, 2, 4, 5

Treatment Approach

• The National Comprehensive Cancer Network recommends stabilizing glucose levels with dietary management, diazoxide, or everolimus in patients with insulinoma 1, 6
• Somatostatin analogs should be used with extreme caution in insulinoma patients, as they can suppress counterregulatory hormones and worsen hypoglycemia, according to the National Comprehensive Cancer Network 1, 4, 6
• Surgical resection is the optimal treatment for locoregional insulinomas, with a cure rate of 90%, as recommended by the National Comprehensive Cancer Network 1, 4, 6
• Medical management with diazoxide can be effective for symptom control in patients with insulinoma who are not candidates for surgery, according to the National Comprehensive Cancer Network 1, 6

Common Pitfalls and Caveats

• Proton pump inhibitors can cause spuriously elevated chromogranin A levels, complicating diagnosis, as noted by the National Comprehensive Cancer Network 5, 7, 8
• Somatostatin analogs can worsen hypoglycemia in insulinoma patients and should be used with extreme caution, as recommended by the National Comprehensive Cancer Network 1, 4, 6

Diagnosis and Management of Insulinoma

Diagnostic Criteria

• The National Comprehensive Cancer Network recommends a supervised 48-hour fast to diagnose insulinoma, with hypoglycemia defined as blood glucose <40-45 mg/dL, and insulin level >3 mcIU/mL, C-peptide ≥0.6 ng/mL, and proinsulin levels ≥5 pmol/L at the time of hypoglycemia, with an insulin-to-glucose ratio of 0.3 or greater 9, 10
• Elevated C-peptide levels help differentiate endogenous hyperinsulinemia (insulinoma) from exogenous insulin administration, with C-peptide levels ≥0.6 ng/mL 9

Tumor Localization

• Endoscopic ultrasound (EUS) is the preferred initial localization method, with approximately 82% sensitivity for detecting pancreatic endocrine tumors, and multiphasic CT or MRI scans should be performed to rule out metastatic disease 9, 10
• For difficult cases, selective arterial calcium stimulation test (Imamura-Doppman procedure) can be considered, which involves injecting calcium into selective pancreatic arteries and measuring insulin levels in the hepatic vein 9, 10

Prognosis and Treatment

• While 90% of insulinomas pursue an indolent course and can be cured surgically, proper diagnosis is essential for optimal outcomes, with the National Comprehensive Cancer Network providing guidelines for diagnosis and management 9, 10

Treatment of Insulinoma

Preoperative Management

• The National Comprehensive Cancer Network recommends that symptoms of hormonal excess must be treated to stabilize the patient before surgical excision 11, 12
• Glucose levels should be stabilized using dietary management 12
• Diazoxide is considered first-line medical therapy for managing hypoglycemia due to hyperinsulinism, according to the National Comprehensive Cancer Network 12
• Everolimus can be considered as an alternative for preoperative stabilization, as per the National Comprehensive Cancer Network guidelines 12
• Somatostatin analogs, such as octreotide and lanreotide, should be used with extreme caution in insulinoma patients as they can suppress counterregulatory hormones and precipitously worsen hypoglycemia, as noted by the National Comprehensive Cancer Network 11, 12

Surgical Approach

• The National Comprehensive Cancer Network states that surgical options depend on tumor location and size, with enucleation being the primary treatment for exophytic or peripheral insulinomas 13
• Enucleation can be performed laparoscopically for localized tumors within the body and tail of the pancreas, as recommended by the National Comprehensive Cancer Network 13
• Distal pancreatectomy with preservation of the spleen is an option for tumors in the body/tail that cannot be enucleated, according to the National Comprehensive Cancer Network 13
• Pancreatoduodenectomy is recommended for tumors in the head of the pancreas that are deep, invasive, or close to the main pancreatic duct, as per the National Comprehensive Cancer Network guidelines 13
• Laparoscopic procedures are safe for selected patients with insulinomas and may be associated with shorter hospital stays, as noted by the National Comprehensive Cancer Network 13

Approach to Insulinoma

Preoperative Management

• The National Comprehensive Cancer Network recommends stabilizing glucose levels with dietary management as first-line approach, and considers everolimus as an alternative for preoperative stabilization 14
• The National Comprehensive Cancer Network suggests that somatostatin analogs (octreotide, lanreotide) should be used with extreme caution or avoided entirely in insulinoma patients, as they can precipitously worsen hypoglycemia and result in fatal complications 14
• Administer preoperative trivalent vaccine (pneumococcus, haemophilus influenzae b, meningococcus group c) to all patients who might require splenectomy, as recommended by the National Comprehensive Cancer Network 14

Special Considerations

• The National Comprehensive Cancer Network notes that patients with life-limiting comorbidities or high surgical risk may require medical management with diazoxide for effective symptom control 14

Insulinoma Imaging Guidelines

Initial Non-Invasive Imaging

• Dual-phase multidetector CT has a sensitivity of 57-94% for pancreatic neuroendocrine tumors and should be performed first to rule out metastatic disease, as recommended by the American Gastroenterological Association 15
• MRI demonstrates comparable sensitivity of 74-94% and serves as an excellent alternative or complementary modality to CT, according to the American College of Radiology 15
• These cross-sectional imaging studies are essential for initial assessment and surgical planning, though they may miss small lesions, with a strength of evidence level of moderate, as stated by the National Comprehensive Cancer Network 15, 16

Endoscopic Ultrasound (EUS)

• EUS is highly sensitive (82-93%) and should be performed in all cases where cross-sectional imaging is negative or equivocal, as recommended by the American Society for Gastrointestinal Endoscopy 15, 16, 17
• EUS serves dual purposes: tumor localization and tissue sampling via fine needle aspiration, with close correlation between aspiration cytology and final histology, with a high level of evidence, as stated by the European Society of Gastrointestinal Endoscopy 15, 17
• This modality is particularly valuable for detecting small tumors and multiple lesions in MEN1 or VHL syndromes that cross-sectional imaging may miss, with a strength of evidence level of high, as recommended by the Endocrine Society 15, 16

Advanced Functional Imaging

• 68Ga-DOTATOC/DOTATATE PET/CT demonstrates the highest sensitivity (87-96%) for pancreatic neuroendocrine tumors and should be considered when conventional imaging is negative, as recommended by the Society of Nuclear Medicine and Molecular Imaging 15, 17
• Somatostatin receptor scintigraphy (SSRS) has limited utility for insulinomas specifically, with only 50-60% sensitivity, compared to 75% for other pancreatic NETs, with a strength of evidence level of low, as stated by the European Association of Nuclear Medicine 15, 17

Invasive Localization Techniques

• Selective arterial calcium stimulation with hepatic venous sampling achieves up to 90% success rate for localizing occult insulinomas and should be reserved for cases where non-invasive imaging fails, as recommended by the American Hepato-Pancreato-Biliary Association 15, 16, 17
• This technique regionalizes the tumor to specific pancreatic arterial territories and must be interpreted in combination with other imaging modalities, with a strength of evidence level of moderate, as stated by the Society for Surgery of the Alimentary Tract 15, 16

Intraoperative Localization

• Intraoperative ultrasound (IOUS) is mandatory and improves sensitivity to 92-97% for identifying small lesions, particularly in the pancreatic head, as recommended by the American College of Surgeons 15, 16, 17
• IOUS enhances detection beyond all preoperative imaging modalities and serves as a useful adjunct to surgical palpation, with a high level of evidence, as stated by the European Society of Surgical Oncology 15, 17

Recommended Imaging Algorithm

• Start with dual-phase CT or MRI to assess for metastatic disease and initial tumor localization, as recommended by the National Comprehensive Cancer Network 15
• Add EUS for all patients to improve detection of small tumors and obtain tissue diagnosis, with a strength of evidence level of high, as recommended by the American Society for Gastrointestinal Endoscopy 15
• Reserve selective arterial calcium stimulation for truly occult cases where all non-invasive studies are negative, as recommended by the American Hepato-Pancreato-Biliary Association 15, 16
• Plan for mandatory IOUS at the time of surgery regardless of preoperative imaging results, with a high level of evidence, as stated by the American College of Surgeons 15

Critical Pitfalls

• Avoid relying solely on SSRS for insulinoma detection, as its sensitivity is only 50-60%, significantly lower than for other pancreatic NETs, with a strength of evidence level of low, as stated by the European Association of Nuclear Medicine 15, 17

Insulinoma Diagnosis and Management

Diagnostic Criteria

• The National Comprehensive Cancer Network recommends measuring insulin level (>3 mcIU/mL), C-peptide (≥0.6 ng/mL), and proinsulin (≥5 pmol/L) during a supervised fast when glucose falls below 55 mg/dL, with a diagnostic sensitivity of 94.5% for insulinomas within 48 hours 18
• The National Comprehensive Cancer Network suggests that proinsulin should be measured routinely during the fast, as even mild elevations can independently indicate aberrant insulin secretion, with 90% of insulinoma patients having elevated proinsulin at the beginning of the fast 18

Localization and Imaging

• The National Comprehensive Cancer Network recommends endoscopic ultrasound (EUS) as the preferred initial localization method, with 82-93% sensitivity for detecting pancreatic neuroendocrine tumors 18
• The National Comprehensive Cancer Network suggests that selective arterial calcium stimulation with hepatic venous sampling (Imamura-Doppman procedure) achieves up to 90% success rate for localizing occult insulinomas, and should be reserved for persistent/recurrent insulinoma or when other localization tests are inconclusive 18

Critical Pitfalls to Avoid

• The National Comprehensive Cancer Network advises against relying on somatostatin receptor scintigraphy (SSRS) for insulinoma detection, as its sensitivity is only 50-60%, and recommends its use only if octreotide or lanreotide is being considered for metastatic disease treatment 18
• The National Comprehensive Cancer Network recommends avoiding measuring chromogranin A in patients on proton pump inhibitors, as these medications cause spuriously elevated levels, and suggests that patients must be off proton pump inhibitors for at least 1 week before testing 18

Treatment Approach

• The National Comprehensive Cancer Network recommends stabilizing glucose levels with dietary management first, followed by diazoxide as first-line medical therapy for managing hypoglycemia, and suggests that everolimus can be considered as an alternative for preoperative stabilization 18
• The National Comprehensive Cancer Network advises that somatostatin analogs (octreotide, lanreotide) must be used with extreme caution or avoided entirely, as they can suppress counterregulatory hormones and precipitously worsen hypoglycemia, potentially causing fatal complications 18
• The National Comprehensive Cancer Network recommends surgical resection as the optimal treatment for locoregional insulinomas, with a 90% cure rate, and suggests that surgical options depend on tumor location, including enucleation, distal pancreatectomy with splenic preservation, and pancreatoduodenectomy 18

Key Laboratory Diagnostic Indicators for Insulinoma

Biochemical Patterns Indicative of Insulinoma

• In patients with suspected insulinoma, the presence of inappropriately elevated plasma insulin concentrations despite low glucose levels is a hallmark that distinguishes insulinoma from other causes of hypoglycemia【19】.
• An elevated fasting proinsulin‑to‑insulin ratio strongly suggests an islet‑cell tumor in individuals presenting with hypoglycemia【19】.
• When hypoglycemia occurs without the accompanying elevations in insulin, C‑peptide, and proinsulin, insulinoma becomes unlikely and alternative etiologies should be pursued【19】.

Role of C‑Peptide in Excluding Factitious Hypoglycemia

• Measurement of C‑peptide is essential to differentiate true insulinoma–mediated hypoglycemia from surreptitious (factitious) insulin administration; low C‑peptide (<0.6 ng/mL) indicates exogenous insulin use, whereas elevated C‑peptide supports endogenous secretion【19】.
• In the diagnostic algorithm for suspected insulinoma, confirming that C‑peptide is elevated helps exclude factitious hypoglycemia caused by exogenous insulin【19】.

Everolimus‑Induced Hyperglycemia: Risk Assessment and Management

Mechanism‑Related Risk Factors

• In patients who develop hyperglycemia while on lanreotide, the finding signals already compromised glucose homeostasis and may reflect either successful suppression of an insulinoma or the unmasking of underlying impaired glucose tolerance【20】.

Baseline Patient Characteristics that Heighten Risk

• Pre‑existing impaired glucose tolerance markedly increases the likelihood of hyperglycemia after initiating everolimus; the 2024 DCRM (Diabetes Care and Research in Metabolism) guidelines emphasize that individuals with pre‑diabetes are at elevated risk for progression to type 2 diabetes, and this risk escalates as pre‑diabetes advances【21】.

Pre‑Treatment Evaluation (Guideline‑Based)

• Prior to everolimus initiation, obtain a baseline fasting plasma glucose, HbA1c, and lipid panel to characterize metabolic status【22】.
• Verify that the patient has access to home glucose‑monitoring tools (glucometer or continuous glucose monitor) to enable early detection of hyperglycemia【22】.
• Establish a coordinated management plan with an endocrinologist for prompt intervention should hyperglycemia develop【22】【23】.

First‑Line Pharmacologic Management (Consensus Recommendation)

• Metformin is recommended as the initial pharmacologic therapy for everolimus‑induced hyperglycemia; the 2009 ADA/EASD consensus algorithm prioritizes metformin for drug‑induced insulin‑resistance hyperglycemia, with insulin‑sensitizing agents preferred in this context【23】.

Monitoring Strategy (Guideline Recommendation)

• Check fasting glucose weekly during the first month after starting everolimus, then monthly thereafter if values remain stable【22】.
• Actively monitor for classic hyperglycemia symptoms—polyuria, polydipsia, and unexplained weight loss—to facilitate timely clinical response【22】.
• Consider continuous glucose monitoring for patients who have difficulty recognizing hyperglycemic symptoms or who require tighter glycemic control【22】.

Diagnostic Glucose Thresholds for Insulinoma

Biochemical Diagnostic Criteria

• The diagnostic glucose threshold for insulinoma is generally defined as a plasma glucose level < 40–45 mg/dL (2.2–2.5 mmol/L); however, many experts accept a level < 55 mg/dL (3.0 mmol/L) as sufficient when it is accompanied by inappropriate insulin secretion. 24

Diagnostic Criteria Distinguishing Insulinoma from Reactive Hypoglycemia

Biochemical Hallmarks

• In patients undergoing a supervised fast, a C‑peptide level of approximately 0.34 ng/mL (≈114 pmol/L) at a glucose concentration of 2.9 mmol/L is inappropriately elevated and supports autonomous insulin secretion characteristic of insulinoma. 25
• Insulinoma is defined by the presence of detectable and elevated insulin and C‑peptide despite severe hypoglycemia, reflecting autonomous secretion. 25

Clinical Timing Differences

• Reactive (post‑prandial) hypoglycemia typically occurs 2–5 hours after meals, whereas fasting hypoglycemia during a 72‑hour supervised fast is indicative of insulinoma. 25
• During fasting hypoglycemia, individuals with reactive hypoglycemia would exhibit suppressed insulin and C‑peptide levels, in contrast to the elevated values observed in insulinoma. 25

Interpretation of Hormone Levels

• The 72‑hour supervised fast is the standard diagnostic test for fasting hypoglycemia and serves as the hallmark clinical presentation used to identify insulinoma. 25